VivoSeq
Other

Surgery

4

Pipeline Programs

39

Active Trials

16

Companies Involved

Surgery is an early-stage landscape with 4 programs across 16 companies. The most active players are Exela Pharma Sciences, LLC., Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Sun Pharma. 2 therapies are approved.

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

34/100

Mech. Concentration

25/100

Completion Rate

78/100

Attrition Rate

15/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

233

clinical trials

Completed130 · 56%
Unknown status28 · 12%
Terminated22 · 9%
Recruiting20 · 9%
Withdrawn14 · 6%
Not yet recruiting10 · 4%
Other9 · 4%

Trial Activity

233 trials

Dronabinol After Arthroscopic Surgery
Recruiting·NNorthwestern University·Phase 3·NCT05335252·30 enrolled
Zinc Oxide Versus Petrolatum Following Skin Surgery
Recruiting··Phase 1·NCT03561376·30 enrolled
Reboxetine for Sleep Apnoea After ENT Surgery
Recruiting·FFlinders University·Phase 2·NCT05978505·20 enrolled
Nalbuphine in ARDS Patients After Surgery
Recruiting··Phase 4·NCT06037330·60 enrolled
PEG3350 vs Senna After Urogyn Surgery
Recruiting·SSt. Joseph's Health, New York·Phase 4·NCT06825260·254 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)